It inhibits bacterial DNA replication, transcription and repair processes by inhibiting bacterial DNA gyrase and topoisomerase IV. It has antibacterial activity against the following microorganisms: Gram-positive bacteria (such as Staphylococcus aureus, Streptococcus pneumoniae), Gram-negative bacteria (such as Escherichia coli, Haemophilus influenzae and parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Neisseria gonorrhoeae, Proteus mirabilis), and other microorganisms (such as Chlamydia pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae).

The modification of lipids is achieved by activating peroxisome proliferator-activated receptor a (PPARa). Through this mechanism, fenofibric acid activates lipoprotein lipase and reduces the production of ApoCIII (lipoprotein lipase inhibitor), thereby increasing fat decomposition and eliminating triglyceride-rich particles in plasma. The reduction of TG causes changes in the size and composition of LDL, from small dense particles to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are rapidly degraded. The activation of PPARa also induces increased synthesis of HDL-C, ApoAI and AII. Fenofibrate can also reduce serum uric acid levels in patients with hyperuricemia and normal people by increasing the urinary excretion of uric acid.

No specific mention from the above information

Broad-spectrum antiviral drug. It has the effect of inhibiting the growth of multiple viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc. in vitro. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, impairing viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus.

This product is a nitroimidazole derivative that can inhibit the target=_blank redox reaction of amoeba and break the nitrogen chain of the protozoa. In vitro tests have shown that when the drug concentration is 1~2mg/L, the histolytica amoeba can undergo morphological changes in 6~20 hours and all are killed within 24 hours. When the concentration is 0.2mg/L, the histolytica amoeba can be killed within 72 hours. This product has a strong effect of killing trichomonas, and its mechanism is unknown. Metronidazole has a killing effect on anaerobic microorganisms. The metabolites generated when it is reduced in the human body also have anti-anaerobic effects, inhibiting the synthesis of bacterial deoxyribonucleic acid, thereby interfering with the growth and reproduction of bacteria, and ultimately causing bacterial death. It has a carcinogenic effect on some animals.